Acne of medium severity, especially indicated in retentional acne

Skin channel.

Apply the value of a pea of ​​cream by spreading it over the lesions, acne-free by avoiding the eyes and lips, once a day before bedtime after washing and drying the skin
< Br>

Clinical improvement should be visible after 4 to 8 weeks of treatment with a clear improvement after 3 months of treatment. The tolerance of adapalene cream was demonstrated over a period of 6 months of treatment. It is recommended to evaluate the improvement of the patient after 3 months of treatment

In the event of discontinuation of treatment or reduction in the frequency of applications due to irritation, it is possible to resume or to increase the rate of application according to the patient's tolerance to treatment.

An increase in the amounts applied would not improve either the activity or the rapidity of action of the product but could cause redness, scaling and discomfort. >
No information in the marketing authorization.

(D. Dermatology)

Although in acne treatment a combination therapy is common, the classification retained: severe acne, medium acne, minor acne, moderate acne has been established in the context of a monotherapy.
< Br>

Adapalene is a chemically stable retinoid compound with anti-inflammatory properties. In terms of the mechanism of action, adapalene binds in the same way as tretinoin to specific, nuclear receptors but not to the cytosolic receptor protein. Br>
Adapalene has comedolytic activity in the rhino mouse model and also has effects on abnormal keratinization and differentiation processes, both of which are present in the pathogenesis of acne. The mode of action of adapalene appears to be a normalization of the cohesion of the follicular epithelial cells which results in a decrease in the formation of microcomedones. >

Adapalene has anti-inflammatory activity in vivo and in vitro (anti-inflammatory tests, standards). Adapalene works by inhibiting the chemotactic and chemokinetic responses of leukocytes, human polynuclear cells and the metabolism of arachidonic acid by lipo-oxidation in inflammatory stimuli. This pharmacological profile may leave an expectation of adapalene activity on the inflammatory component of acne.

Hypersensitivity to any of the components.

Special warnings

This medicinal product contains "Parahydroxybenzoate" and may cause allergic reactions (possibly delayed).
Precautions for use

If a hypersensitivity reaction or severe irritation reaction occurs, the use of the cream should be temporarily or even permanently discontinued.
Because of the slightly irritating character of the cream, the use of cosmetic astringent cleansers and desiccants or irritants (such as products, fragrances or alcohol) is to be avoided.
< Br>

Apply in the morning, for example, erythromycin (4%) or clindamycin (1%) lotions, or in combination with other anti-acne treatments. Aqueous gels with benzoyl peroxide in concentrations of up to 10%.

Exposure to sunlight and ultraviolet lamps will cause additional irritation Avoid exposure during treatment as much as possible

The treatment may, however, be continued if the solar exposure is reduced to a minimum (protection by wearing a hat and use of a sunscreen cream) and the rhythm of applications adjusted. Br>

In case of exceptional exposure to the sun (one day at sea for example), do not apply the day before, the same day and the next day

If prior exposure has resulted in burns ("sunburn"), wait for a full recovery before initiating treatment.

Adapalene is stable to oxygen and light and chemically non-reactive. The use of adapalene with other topical anti-acne medicines, such as clindamycin phosphate or benzoyl peroxide, does not produce mutagenic degradation.

Since adapalene is weakly absorbed by the skin, interaction with systemically administered drugs is therefore unlikely.

Oral toxicity in mice is greater than 10 mg / kg. Despite the low risk of accidental ingestion, consideration should be given to the possibility of gastric lavage.

Like all retinoids, adapalene is teratogenic orally. Teratogenicity studies carried out in the rat and rabbit topically with doses 200 times greater than the human dose did not demonstrate teratogenic effect. >

In the human species, considering the existence of a percutaneous passage (even if it is weak) and the absence of clinical data, the use of adapalene is discouraged during pregnancy. Pregnancy.


Do not apply on breast during breastfeeding.

Reversible irritation of the skin may appear, disappearing when treatment is interrupted or applications spaced. A sensation of heat or a slight tingle can occur after application.
Acne of medium severity, especially indicated in retentional acne